GRAMD1B
Summary:
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| GRAM domain containing 1B | Ensembl:ENSG00000023171 | HGNC:HGNC:29214 | PA142671708 | 11q24.1 |
GO terms in GRAMD1B
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| CC | HDA | GO:0016020 | membrane |
| CC | IEA | GO:0016021 | integral component of membrane |
Gene expression in normal tissue: GRAMD1B
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD506 | Fedratinib | 2 |
| iGMDRD888 | Compound 44 | 1 |
| iGMDRD188 | Piperlongumine | 2 |
| iGMDRD356 | PNU-74654 | 2 |
| iGMDRD444 | Tivantinib | 1 |
| iGMDRD255 | SB225002 | 4 |
| iGMDRD513 | BML-259 | 3 |
| iGMDRD318 | PAC-1 | 3 |
| iGMDRD870 | BRD63610 | 2 |
| iGMDRD187 | BRD9876 | 2 |
| iGMDRD193 | Fqi1 | 1 |
| iGMDRD634 | SCHEMBL2608041 | 11 |
| iGMDRD394 | BX-795 | 2 |
| iGMDRD280 | CYTOCHALASIN B | 3 |
| iGMDRD387 | CHIR-99021 | 1 |
| iGMDRD425 | ERASTIN | 1 |
| iGMDRD420 | Leucascandrolide A | 1 |
| iGMDRD126 | Tipifarnib | 3 |
| iGMDRD781 | Sirolimus | 2 |
| iGMDRD144 | NSC95397 | 2 |
| iGMDRD329 | Merck60 | 7 |
| iGMDRD882 | CIL41 | 2 |
| iGMDRD886 | Compound 1541A | 2 |
| iGMDRD300 | Tozasertib | 2 |
| iGMDRD147 | Prima-1 | 1 |
| iGMDRD202 | Curcumin | 1 |
| iGMDRD289 | Parthenolide | 1 |
| iGMDRD434 | BMS-536924 | 2 |
| iGMDRD351 | GW843682X | 2 |
| iGMDRD341 | Triacsin c | 2 |
| iGMDRD85 | Ursolic acid | 2 |
| iGMDRD123 | Isoevodiamine | 4 |
| iGMDRD248 | BRD4354 | 3 |
| iGMDRD84 | Lovastatin acid | 1 |
| iGMDRD523 | Cyanoquinoline, 11 | 2 |
| iGMDRD532 | Olaparib | 2 |
| iGMDRD150 | RITA | 6 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in GRAMD1B
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.